SuperSonic Imagine to Present at the Cowen and Company 35th Annual Health Care Conference on March 4, 2015


AIX-EN-PROVENCE, FRANCE--(Marketwired - Feb 27, 2015) - SuperSonic Imagine (EURONEXT PARIS: SSI) (Euronext: SSI, FR0010526814), the highly innovative medical imaging company that invented ShearWave™ Elastography and UltraFast Doppler, announced today that it will present at the Cowen and Company 35th Annual Health Care Conference in Boston, MA. Jacques Souquet, Chief Executive Officer, is scheduled to present on Wednesday, March 4th at 10:00a.m. ET.

About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.

Contact Information:

Contact information:

SuperSonic Imagine
Marketing & Communication
Emmanuelle Vella
emmanuelle.vella@supersonicimagine.com
+33 4 86 79 03 27

NewCap
Investor Relations - EU
Pierre Laurent / Florent Alba
supersonicimagine@newcap.fr
+33 1 44 71 98 55

Blueprint Life Science Group
Investor Relations - US
Candice Knoll
cknoll@bplifescience.com
415 375 3340 Ext. 105

ComCorp
Media Relations
Florence Portejoie
fportejoie@comcorp.fr
+33 1 58 18 32 58
+33 6 88 84 81 74
Adelaide Manester
amanester@comcorp.fr
+33 1 58 18 32 58
+33 6 70 45 74 37